SRC and MEK co-inhibition synergistically enhances the anti-tumor effect in both Non-Small Cell Lung Cancer (NSCLC) and erlotinib-resistant NSCLC

Xu, H., Zhang, L., Yuan, M., Xu, L. F., Zhang, J., Kong, S., … Lao, Y. (2019). SRC and MEK co-inhibition synergistically enhances the anti-tumor effect in both Non-Small Cell Lung Cancer (NSCLC) and erlotinib-resistant NSCLC. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2019.00586